Limits...
Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy.

Falcão PL, Motta BM, de Lima FC, Lima CV, Campos TP - Radiol Bras (2015 May-Jun)

Bottom Line: Radiosensitive PBMC showed decrease in viability at 2 Gy, and a more significant decrease at 10 Gy for both dose rates.MDAMB- 231 cells presented viability decrease only at higher dose and dose rate.The results showed MDA-MB-231 clone expansion at low dose rate after 48-72 hours post-radiation.

View Article: PubMed Central - PubMed

Affiliation: Postdoc, Associate Professor at Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.

ABSTRACT

Objective: In the present study, the authors investigated the in vitro behavior of radio-resistant breast adenocarcinoma (MDA-MB-231) cells line and radiosensitive peripheral blood mononuclear cells (PBMC), as a function of different radiation doses, dose rates and postirradiation time kinetics, with a view to the interest of clinical radiotherapy.

Materials and methods: The cells were irradiated with Co-60, at 2 and 10 Gy and two different exposure rates, 339.56 cGy.min(-1) and the other corresponding to one fourth of the standard dose rates, present over a 10-year period of cobalt therapy. Post-irradiation sampling was performed at pre-established kinetics of 24, 48 and 72 hours. The optical density response in viability assay was evaluated and a morphological analysis was performed.

Results: Radiosensitive PBMC showed decrease in viability at 2 Gy, and a more significant decrease at 10 Gy for both dose rates. MDAMB- 231 cells presented viability decrease only at higher dose and dose rate. The results showed MDA-MB-231 clone expansion at low dose rate after 48-72 hours post-radiation.

Conclusion: Low dose rate shows a possible potential clinical impact involving decrease in management of radio-resistant and radiosensitive tumor cell lines in cobalt therapy for breast cancer.

No MeSH data available.


Related in: MedlinePlus

Non-irradiated MDA-MB- 231 cells morphology previously to the experiment, andpost-irradiated at 10 Gy, in a field where apoptotic bodies and still viablecells are seen.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4492568&req=5

f06: Non-irradiated MDA-MB- 231 cells morphology previously to the experiment, andpost-irradiated at 10 Gy, in a field where apoptotic bodies and still viablecells are seen.

Mentions: Figure 6 shows non-irradiated MDA-MB-231 cellsobtained from the control vial, besides irradiated MDA-MB-231 culture wells atdifferent exposure times. The apoptotic cells present with a differentiatedmorphology with respect to size and granularity, being much more granular than thecells which were not damaged by radiation. There are signs of the presence ofvacuoles and apoptotic bodies. There is also the presence of dysmorphic cells withpossible indication of necrosis. It is interesting to notice that the morphologicalfeatures of breast adenocarcinoma MDA-MB-231 cell line had already been previouslyapproached in another study, suggesting deleterious effects at higher doses (10 Gy).Studies developed by Campos et al.(16), which corroborate the findings of the present study, show theanalysis of images of vials with MDA-MB-231 cell line during irradiation andsuggested the presence of apoptotic processes.


Enhancement of viability of radiosensitive (PBMC) and resistant (MDA-MB-231) clones in low-dose-rate cobalt-60 radiation therapy.

Falcão PL, Motta BM, de Lima FC, Lima CV, Campos TP - Radiol Bras (2015 May-Jun)

Non-irradiated MDA-MB- 231 cells morphology previously to the experiment, andpost-irradiated at 10 Gy, in a field where apoptotic bodies and still viablecells are seen.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4492568&req=5

f06: Non-irradiated MDA-MB- 231 cells morphology previously to the experiment, andpost-irradiated at 10 Gy, in a field where apoptotic bodies and still viablecells are seen.
Mentions: Figure 6 shows non-irradiated MDA-MB-231 cellsobtained from the control vial, besides irradiated MDA-MB-231 culture wells atdifferent exposure times. The apoptotic cells present with a differentiatedmorphology with respect to size and granularity, being much more granular than thecells which were not damaged by radiation. There are signs of the presence ofvacuoles and apoptotic bodies. There is also the presence of dysmorphic cells withpossible indication of necrosis. It is interesting to notice that the morphologicalfeatures of breast adenocarcinoma MDA-MB-231 cell line had already been previouslyapproached in another study, suggesting deleterious effects at higher doses (10 Gy).Studies developed by Campos et al.(16), which corroborate the findings of the present study, show theanalysis of images of vials with MDA-MB-231 cell line during irradiation andsuggested the presence of apoptotic processes.

Bottom Line: Radiosensitive PBMC showed decrease in viability at 2 Gy, and a more significant decrease at 10 Gy for both dose rates.MDAMB- 231 cells presented viability decrease only at higher dose and dose rate.The results showed MDA-MB-231 clone expansion at low dose rate after 48-72 hours post-radiation.

View Article: PubMed Central - PubMed

Affiliation: Postdoc, Associate Professor at Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.

ABSTRACT

Objective: In the present study, the authors investigated the in vitro behavior of radio-resistant breast adenocarcinoma (MDA-MB-231) cells line and radiosensitive peripheral blood mononuclear cells (PBMC), as a function of different radiation doses, dose rates and postirradiation time kinetics, with a view to the interest of clinical radiotherapy.

Materials and methods: The cells were irradiated with Co-60, at 2 and 10 Gy and two different exposure rates, 339.56 cGy.min(-1) and the other corresponding to one fourth of the standard dose rates, present over a 10-year period of cobalt therapy. Post-irradiation sampling was performed at pre-established kinetics of 24, 48 and 72 hours. The optical density response in viability assay was evaluated and a morphological analysis was performed.

Results: Radiosensitive PBMC showed decrease in viability at 2 Gy, and a more significant decrease at 10 Gy for both dose rates. MDAMB- 231 cells presented viability decrease only at higher dose and dose rate. The results showed MDA-MB-231 clone expansion at low dose rate after 48-72 hours post-radiation.

Conclusion: Low dose rate shows a possible potential clinical impact involving decrease in management of radio-resistant and radiosensitive tumor cell lines in cobalt therapy for breast cancer.

No MeSH data available.


Related in: MedlinePlus